



For immediate release – October 25, 2012

SALES MOMENTUM CONTINUES IN Q3

Lure (France), October 25, 2012 – Vétoquinol posted sales of €220.9 million for the first 9 months of 2012, up 6.2% compared to the same period last year.

<i>€ millions</i>	2012	2011	<i>Change</i>
September year-to-date sales	220.9	208.1	+6.2%
September year-to-date sales <i>At constant exchange rates</i>	217.2	208.1	+4.4%
September year-to-date sales <i>At constant exchange rates and consolidation scope (like for like)</i>	214.1	208.1	+2.9%

A solid 8.4% Q3 growth

Vétoquinol Group sales for the third quarter of 2012 totaled €74.1 million, up 8.4% on Q3 2011. At constant exchange rates, sales increased by 5.0% and like-for-like growth came in at 4.9%.

Over the same period, sales growth resumed in Europe, the Group's largest territory.

Like-for-like growth, which stood at 1.9% at the end of the first semester 2012, rose to 2.9% for the first nine months of 2012.

These strong sales were driven partly by double-digit growth in the Asia Pacific region (12.8%) and the Americas (19.3%) and partly by the stabilization of Marbocyl[®] sales in Europe.

In Europe, new product launches (Cimalgex[®], Ceftiocyl[®], Forcyl[®] and Flevox[®]) made a significant contribution to sales growth in this territory.

Business outlook

"The strong performance achieved over the first 9 months of the year confirms the Group's return to growth", Vétoquinol CEO Matthieu Frechin affirmed. "The integration of our new subsidiary, Orsco Laboratoire Vétérinaire, is progressing according to plan. Thanks to our strong financial structure, we can continue to review targeted acquisitions in line with our strategy. We also confirm our intention to bolster sales growth and earnings in the short and medium term."

About Vétoquinol

Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group, dedicated exclusively to animal health, is the 10th largest animal healthcare laboratory in the world. More than 80% of its revenues are generated outside France.

Vétoquinol's business includes research and development, production and marketing of medicinal and non-medicinal products. Vétoquinol has positioned itself in the curative sector and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation and cardiology/nephrology.

The Group currently distributes its products in more than one hundred countries throughout Europe, North America and Asia/Pacific, with subsidiaries in 23 countries and a network of 140 distribution partners. The company has 1,800 employees worldwide.

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For more information, contact:

VETOQUINOL

Finance department

Marie-Josée AUBRY-ROTA

Tel.: 03 84 62 59 88

relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor relations

Emmanuel DOVERGNE

Tel.: 01 56 43 44 63

emmanuel.dovergne@keima.fr

Media relations

Alix HÉRIARD DUBREUIL

Tel.: 01 56 43 44 62

alix.heriard@keima.fr

ANNEX

Sales in € million	2012	2011	Change	Change at constant exchange rates	Change at constant exchange rates and scope
1 st quarter	77.0	66.4	+15.9%	+15.7%	+13.0%
2 nd quarter	69.8	73.3	-4.8%	-6.5%	-8.2%
3 th quarter	74.1	68.4	+8.4%	+5.0%	+4.9%
Total year to date sales	220.9	208.1	+6.2%	+4.4%	+2.9%